Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             126 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Alternative business models for drug discovery Bunin, Barry A.
 2011
 15-16 p. 643-645
3 p.
 artikel
2 An early history of the molecular modeling industry Richon, Allen B.
 2008
 15-16 p. 659-664
6 p.
 artikel
3 A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding Bogoyevitch, Marie A
 2007
 15-16 p. 622-633
12 p.
 artikel
4 Animal models of asthma: value, limitations and opportunities for alternative approaches Holmes, Anthony M.
 2011
 15-16 p. 659-670
12 p.
 artikel
5 A procedural framework for good imaging practice in pharmacological fMRI studies applied to drug development #2: protocol optimization and best practices Schwarz, Adam J.
 2011
 15-16 p. 671-682
12 p.
 artikel
6 August Diary 2007
 15-16 p. 682-
1 p.
 artikel
7 Biaryl piperidine melanin-concentrating hormone-1 receptor antagonists for obesity Edwards, Paul
 2006
 15-16 p. 770-771
2 p.
 artikel
8 Biologics: the next generation of analgesic drugs? Chessell, Iain P.
 2012
 15-16 p. 875-879
5 p.
 artikel
9 Biopharma business models in Canada March-Chordà, I.
 2011
 15-16 p. 654-658
5 p.
 artikel
10 Can Drosophila melanogaster represent a model system for the detection of reproductive adverse drug reactions? Avanesian, Agnesa
 2009
 15-16 p. 761-766
6 p.
 artikel
11 Can network pharmacology rescue neutraceutical cancer research? Azmi, Asfar S.
 2012
 15-16 p. 807-809
3 p.
 artikel
12 Can we estimate the accuracy of ADME–Tox predictions? Tetko, Igor V.
 2006
 15-16 p. 700-707
8 p.
 artikel
13 Cell culture metabolomics: applications and future directions Čuperlović-Culf, Miroslava
 2010
 15-16 p. 610-621
12 p.
 artikel
14 Cell-penetrating peptides: classes, origin, and current landscape Milletti, Francesca
 2012
 15-16 p. 850-860
11 p.
 artikel
15 Characteristics of rare disease marketing applications associated with FDA product approvals 2006–2010 Pariser, Anne R.
 2012
 15-16 p. 898-904
7 p.
 artikel
16 Chemistry strategies in early drug discovery: an overview of recent trends Colombo, Matteo
 2008
 15-16 p. 677-684
8 p.
 artikel
17 Clinical research in China and India: a paradigm shift in drug development Singh, Romi
 2006
 15-16 p. 675-676
2 p.
 artikel
18 Computational mapping tools for drug discovery Ivanenkov, Yan A.
 2009
 15-16 p. 767-775
9 p.
 artikel
19 Contents 2009
 15-16 p. iii-
1 p.
 artikel
20 Contents 2009
 15-16 p. i-
1 p.
 artikel
21 Contents 2007
 15-16 p. iii-
1 p.
 artikel
22 Contents 2008
 15-16 p. iii-
1 p.
 artikel
23 Contents 2008
 15-16 p. i-
1 p.
 artikel
24 Contents 2013
 15-16 p. iii-
1 p.
 artikel
25 Contents 2013
 15-16 p. i-
1 p.
 artikel
26 Contents 2012
 15-16 p. i-
1 p.
 artikel
27 Contents 2012
 15-16 p. iii-
1 p.
 artikel
28 Contents page 1 2010
 15-16 p. i-
1 p.
 artikel
29 Contents page 2 2010
 15-16 p. iii-
1 p.
 artikel
30 Contents page 2 2011
 15-16 p. iii-
1 p.
 artikel
31 Contents page 1 2011
 15-16 p. i-
1 p.
 artikel
32 Current endovascular treatment of acute stroke and future aspects Killer, Monika
 2010
 15-16 p. 640-647
8 p.
 artikel
33 Current status and future direction of the molecular modeling industry Richon, Allen B.
 2008
 15-16 p. 665-669
5 p.
 artikel
34 Current status of liposomal porphyrinoid photosensitizers Skupin-Mrugalska, Paulina
 2013
 15-16 p. 776-784
9 p.
 artikel
35 Cysteamine: an old drug with new potential Besouw, Martine
 2013
 15-16 p. 785-792
8 p.
 artikel
36 DARPins: A new generation of protein therapeutics Stumpp, Michael T.
 2008
 15-16 p. 695-701
7 p.
 artikel
37 Data structures and computational tools for the extraction of SAR information from large compound sets Wawer, Mathias
 2010
 15-16 p. 630-639
10 p.
 artikel
38 Denmark: going from strength to strength Jensen, Louise Wendt
 2008
 15-16 p. 637-639
3 p.
 artikel
39 Design and synthesis of a novel DNA-encoded chemical library Edwards, Paul
 2010
 15-16 p. 690-691
2 p.
 artikel
40 Designed multiple ligands in metabolic disease research: from concept to platform Gattrell, W.
 2013
 15-16 p. 692-696
5 p.
 artikel
41 Diary Vol/ISS 11/15 2006
 15-16 p. 772-
1 p.
 artikel
42 DNA demethylases: a new epigenetic frontier in drug discovery Carey, Nessa
 2011
 15-16 p. 683-690
8 p.
 artikel
43 DNA polymerase beta (pol β) inhibitors: A comprehensive overview Barakat, Khaled H.
 2012
 15-16 p. 913-920
8 p.
 artikel
44 Drug discovery chemistry: a primer for the non-specialist Jordan, Allan M.
 2009
 15-16 p. 731-744
14 p.
 artikel
45 Drug discovery in the extracellular matrix Huxley-Jones, Julie
 2008
 15-16 p. 685-694
10 p.
 artikel
46 Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery Pérot, Stéphanie
 2010
 15-16 p. 656-667
12 p.
 artikel
47 Drug metabolism in the paediatric population and in the elderly Benedetti, Margherita Strolin
 2007
 15-16 p. 599-610
12 p.
 artikel
48 Drug resistance: a growing problem Peet, Norton P.
 2010
 15-16 p. 583-586
4 p.
 artikel
49 Editorial Board 2007
 15-16 p. v-
1 p.
 artikel
50 ELN implementation challenges Drake, David J.
 2007
 15-16 p. 647-649
3 p.
 artikel
51 Erratum to: Heparin/heparan sulphate-based drugs Gandhi, Neha S.
 2011
 15-16 p. 741-
1 p.
 artikel
52 Evaluation of novel drugs using fMRI in early-phase clinical trials: safety monitoring George, Edward
 2010
 15-16 p. 684-689
6 p.
 artikel
53 Evidence-based approach to assess passive diffusion and carrier-mediated drug transport Di, Li
 2012
 15-16 p. 905-912
8 p.
 artikel
54 Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation? Ahmed, Mohamed H.
 2010
 15-16 p. 590-595
6 p.
 artikel
55 FDA-approved drug labeling for the study of drug-induced liver injury Chen, Minjun
 2011
 15-16 p. 697-703
7 p.
 artikel
56 Fluorine local environment: from screening to drug design Vulpetti, Anna
 2012
 15-16 p. 890-897
8 p.
 artikel
57 Following up high-throughput screening with parallel chemistry for the generation of actives against biological targets Edwards, Paul
 2008
 15-16 p. 723-725
3 p.
 artikel
58 Follow-on drugs: How far should chemists look? Giordanetto, Fabrizio
 2011
 15-16 p. 722-732
11 p.
 artikel
59 French/European academic compound library initiative Hibert, Marcel F.
 2009
 15-16 p. 723-725
3 p.
 artikel
60 Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity Hill, Alan P.
 2010
 15-16 p. 648-655
8 p.
 artikel
61 Hammerhead ribozymes in therapeutic target discovery and validation Tedeschi, Lorena
 2009
 15-16 p. 776-783
8 p.
 artikel
62 Hit discovery and hit-to-lead approaches Keserű, György M.
 2006
 15-16 p. 741-748
8 p.
 artikel
63 ‘Hot’ bacterial viruses shed more light on genetic instability Demidov, Vadim V.
 2008
 15-16 p. 726-727
2 p.
 artikel
64 HTS technologies in biopharmaceutical discovery Wu, Ge
 2006
 15-16 p. 718-724
7 p.
 artikel
65 Identification of drugs that interact with herbs in drug development Zhou, Shu-Feng
 2007
 15-16 p. 664-673
10 p.
 artikel
66 Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses Barbosa, Maria D.F.S.
 2007
 15-16 p. 674-681
8 p.
 artikel
67 Increasing the reliability of protein interactomes Chua, Hon Nian
 2008
 15-16 p. 652-658
7 p.
 artikel
68 Inhibition of proteases as a novel therapeutic strategy in the treatment of metabolic, inflammatory and functional diseases of the gastrointestinal tract Sałaga, Maciej
 2013
 15-16 p. 708-715
8 p.
 artikel
69 Inorganic hollow nanoparticles and nanotubes in nanomedicine Son, Sang Jun
 2007
 15-16 p. 650-656
7 p.
 artikel
70 Inorganic hollow nanoparticles and nanotubes in nanomedicine Son, Sang Jun
 2007
 15-16 p. 657-663
7 p.
 artikel
71 Insight into the structural determinants for selective inhibition of matrix metalloproteinases Pirard, Bernard
 2007
 15-16 p. 640-646
7 p.
 artikel
72 Is autologous chondrocyte implantation (ACI) an adequate treatment option for repair of cartilage defects in paediatric patients? Kaszkin-Bettag, Marietta
 2013
 15-16 p. 740-747
8 p.
 artikel
73 Major advances in the development of histamine H4 receptor ligands Smits, Rogier A.
 2009
 15-16 p. 745-753
9 p.
 artikel
74 Matched Molecular Pair Analysis in drug discovery Dossetter, Alexander G.
 2013
 15-16 p. 724-731
8 p.
 artikel
75 Memo to the FDA and ICH: appeal for in vivo drug target identification and target pharmacokinetics Stumpf, Walter E
 2007
 15-16 p. 594-598
5 p.
 artikel
76 Methods for mining HTS data Harper, Gavin
 2006
 15-16 p. 694-699
6 p.
 artikel
77 Microtissue size and hypoxia in HTS with 3D cultures Asthana, Amish
 2012
 15-16 p. 810-817
8 p.
 artikel
78 Model-based drug discovery: implementation and impact Visser, Sandra A.G.
 2013
 15-16 p. 764-775
12 p.
 artikel
79 Modulating TNF-α signaling with natural products Paul, Atish T.
 2006
 15-16 p. 725-732
8 p.
 artikel
80 Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery – the GSK experience Vanderwall, Dana E.
 2011
 15-16 p. 646-653
8 p.
 artikel
81 Molecular simulations of carbohydrates and protein–carbohydrate interactions: motivation, issues and prospects Fadda, Elisa
 2010
 15-16 p. 596-609
14 p.
 artikel
82 Molecular understanding of curcumin in diabetic nephropathy Soetikno, Vivian
 2013
 15-16 p. 756-763
8 p.
 artikel
83 mTOR as a multifunctional therapeutic target in HIV infection Nicoletti, Ferdinando
 2011
 15-16 p. 715-721
7 p.
 artikel
84 Multipotent antioxidants: from screening to design Zhang, Hong-Yu
 2006
 15-16 p. 749-754
6 p.
 artikel
85 Needed: system dynamics for the drug discovery process Sirois, Suzanne
 2008
 15-16 p. 708-715
8 p.
 artikel
86 Network analysis has diverse roles in drug discovery Hasan, Samiul
 2012
 15-16 p. 869-874
6 p.
 artikel
87 New Court guidance on repackaging of parallel traded products Wright, Elisabethann
 2007
 15-16 p. 591-593
3 p.
 artikel
88 New tools for functional genomic analysis Chen, Xin
 2009
 15-16 p. 754-760
7 p.
 artikel
89 New Zealand: unique biodiversity and world-class science converge Boalch, Chris
 2006
 15-16 p. 677-680
4 p.
 artikel
90 Non-peptidyl insulin mimetics as a potential antidiabetic agent Nankar, Rakesh P.
 2013
 15-16 p. 748-755
8 p.
 artikel
91 Orphan drug development across Europe: bottlenecks and opportunities Heemstra, Harald E.
 2008
 15-16 p. 670-676
7 p.
 artikel
92 Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only Kell, Douglas B.
 2011
 15-16 p. 704-714
11 p.
 artikel
93 Pharmacokinetics and the drug–target residence time concept Dahl, Göran
 2013
 15-16 p. 697-707
11 p.
 artikel
94 Physiological, pathological and potential therapeutic roles of adipokines Falcão-Pires, Inês
 2012
 15-16 p. 880-889
10 p.
 artikel
95 Potentiation strategies of dendritic cell-based antitumor vaccines: combinational therapy takes the front seat Torabi-Rahvar, Monireh
 2011
 15-16 p. 733-740
8 p.
 artikel
96 Preclinical assessment of cardiac toxicity Kettenhofen, Ralf
 2008
 15-16 p. 702-707
6 p.
 artikel
97 Progress and problems in the exploration of therapeutic targets 2006
 15-16 p. 717-
1 p.
 artikel
98 Progressing preclinical drug candidates: strategies on preclinical safety studies and the quest for adequate exposure Higgins, John
 2012
 15-16 p. 828-836
9 p.
 artikel
99 Progress in the development of peroxide-based anti-parasitic agents Muraleedharan, K.M.
 2009
 15-16 p. 793-803
11 p.
 artikel
100 Pyrimidin-4-yl phenols as anti-infective agents Edwards, Paul
 2006
 15-16 p. 768-769
2 p.
 artikel
101 R&D investments for neglected diseases can be sensitive to the economic goal of pharmaceutical companies Dimitri, Nicola
 2012
 15-16 p. 818-823
6 p.
 artikel
102 Recent advances in glucokinase activators for the treatment of type 2 diabetes Pal, Manojit
 2009
 15-16 p. 784-792
9 p.
 artikel
103 Recent PDE4 inhibitor clinical candidates Yeung, Kap-Sun
 2009
 15-16 p. 812-813
2 p.
 artikel
104 Relaxin family peptide receptors – from orphans to therapeutic targets van der Westhuizen, Emma T.
 2008
 15-16 p. 640-651
12 p.
 artikel
105 Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases Dong, Ming
 2010
 15-16 p. 622-629
8 p.
 artikel
106 ROCK: the Roche medicinal chemistry knowledge application – design, use and impact Mayweg, Alexander
 2011
 15-16 p. 691-696
6 p.
 artikel
107 Screening the receptorome: an efficient approach for drug discovery and target validation Strachan, Ryan T.
 2006
 15-16 p. 708-716
9 p.
 artikel
108 Seeding drug discovery: integrating telomerase cancer biology and cellular senescence to uncover new therapeutic opportunities in targeting cancer stem cells Keith, W Nicol
 2007
 15-16 p. 611-621
11 p.
 artikel
109 Strategic alliances and market risk Havenaar, Matthias
 2012
 15-16 p. 824-827
4 p.
 artikel
110 Strategic groups in the biopharmaceutical industry: implications for performance Erden, Zeynep
 2009
 15-16 p. 726-730
5 p.
 artikel
111 Strategies to support drug discovery through integration of systems and data Waller, Chris L.
 2007
 15-16 p. 634-639
6 p.
 artikel
112 Synthetic library design Huwe, Christoph M.
 2006
 15-16 p. 763-767
5 p.
 artikel
113 Systematic characterization of structure–activity relationships and ADMET compliance: a case study Yongye, Austin B.
 2013
 15-16 p. 732-739
8 p.
 artikel
114 Targeting atypical trypanosomatid DNA topoisomerase I Balaña-Fouce, Rafael
 2006
 15-16 p. 733-740
8 p.
 artikel
115 Targeting mTOR as a novel therapeutic strategy for traumatic CNS injuries Arachchige Don, Aruni S.
 2012
 15-16 p. 861-868
8 p.
 artikel
116 The challenges of product development and commercialization in a convergence technology world: focus on regenerative medicine Tozer, Dean
 2010
 15-16 p. 587-589
3 p.
 artikel
117 The Drug Discovery Portal: a resource to enhance drug discovery from academia Clark, Rachel L.
 2010
 15-16 p. 679-683
5 p.
 artikel
118 The future is here: tumour profiling in day-to-day clinical practice Lemech, Charlotte R.
 2013
 15-16 p. 689-691
3 p.
 artikel
119 The impact of interferon-β treatment on the blood–brain barrier Kraus, Jörg
 2006
 15-16 p. 755-762
8 p.
 artikel
120 Therapeutic strategies for the treatment of stroke Green, A. Richard
 2006
 15-16 p. 681-693
13 p.
 artikel
121 The solution-phase design and synthesis of libraries for the discovery of CNS active substances Edwards, Paul John
 2011
 15-16 p. 742-744
3 p.
 artikel
122 The Tox21 robotic platform for the assessment of environmental chemicals – from vision to reality Attene-Ramos, Matias S.
 2013
 15-16 p. 716-723
8 p.
 artikel
123 The value of proteasome inhibition in cancer Cvek, Boris
 2008
 15-16 p. 716-722
7 p.
 artikel
124 Traditional medicine-inspired approaches to drug discovery: can Ayurveda show the way forward? Patwardhan, Bhushan
 2009
 15-16 p. 804-811
8 p.
 artikel
125 Translation of drug effects from experimental models of neuropathic pain and analgesia to humans Taneja, Amit
 2012
 15-16 p. 837-849
13 p.
 artikel
126 What made sesquiterpene lactones reach cancer clinical trials? Ghantous, Akram
 2010
 15-16 p. 668-678
11 p.
 artikel
                             126 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland